OncoMatch/Clinical Trials/NCT06607419
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Is NCT06607419 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Blinatumomab for b-cell lymphoblastic leukemia.
Treatment: Blinatumomab — The goal of this clinical trial is to evaluate the efficacy of Blinatumomab in pediatric patient with newly diagnosed acute B-Lymphoblastic leukemia with poor response to early chemotherapy, i.e. day 19 MRD ≥ 0.1% (low-risk) or day 19 MRD ≥ 0.01% (intermediate-risk). The main question is: • If the flow cytometric MRD negative (\<0.01%) rate and the NGS- MRD negative (\<0.0001%) rate at the end of induction for patients received Blinatumomab will be superior to historical control (D46MRD in the CCCG-ALL2020 protocol). Participants will: * Take 14 days full dose Blinatumomab; * With bone marrow evaluated before and after Blinatumomab treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Acute Lymphoblastic Leukemia
Disease stage
Excluded: Stage INITIAL DIAGNOSIS OF HIGH RISK
Initial diagnosis of high risk [excluded]
Demographics
Prior therapy
Cannot have received: glucocorticoid
Treated with glucocorticoids for ≥14 days within one month before enrollment
Cannot have received: ABL kinase inhibitor
ABL kinase inhibitors for > 7 days within one month before enrollment
Cannot have received: chemotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: radiotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06607419 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages